What is the official website of HollisterStier Allergy ?

The official website of HollisterStier Allergy is http://www.hsallergy.com.

What is HollisterStier Allergy's cybersecurity risk score?

HollisterStier Allergy has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has HollisterStier Allergy experienced?

According to Rankiteo, HollisterStier Allergy currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has HollisterStier Allergy been affected by any supply chain cyber incidents ?

According to Rankiteo, HollisterStier Allergy has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does HollisterStier Allergy have SOC 2 Type 1 certification ?

According to Rankiteo, HollisterStier Allergy is not certified under SOC 2 Type 1.

Does HollisterStier Allergy have SOC 2 Type 2 certification ?

According to Rankiteo, HollisterStier Allergy does not hold a SOC 2 Type 2 certification.

Does HollisterStier Allergy comply with GDPR ?

According to Rankiteo, HollisterStier Allergy is not listed as GDPR compliant.

Does HollisterStier Allergy have PCI DSS certification ?

According to Rankiteo, HollisterStier Allergy does not currently maintain PCI DSS compliance.

Does HollisterStier Allergy comply with HIPAA ?

According to Rankiteo, HollisterStier Allergy is not compliant with HIPAA regulations.

Does HollisterStier Allergy have ISO 27001 certification ?

According to Rankiteo,HollisterStier Allergy is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does HollisterStier Allergy operate in ?

HollisterStier Allergy operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does HollisterStier Allergy have ?

HollisterStier Allergy employs approximately 126 people worldwide.

Does HollisterStier Allergy own any subsidiaries ?

HollisterStier Allergy presently has no subsidiaries across any sectors.

How many LinkedIn followers does HollisterStier Allergy have ?

HollisterStier Allergy's official LinkedIn profile has approximately 1,339 followers.

Does HollisterStier Allergy have a Crunchbase profile ?

No, HollisterStier Allergy does not have a profile on Crunchbase.

Does HollisterStier Allergy have a LinkedIn profile ?

Yes, HollisterStier Allergy maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/hollisterstier-allergy.

How many cybersecurity incidents has HollisterStier Allergy experienced ?

As of June 18, 2026, Rankiteo reports that HollisterStier Allergy has not experienced any cybersecurity incidents.

How many peer or competitor companies does HollisterStier Allergy have ?

HollisterStier Allergy has an estimated 5,692 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

HollisterStier Allergy

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

HollisterStier Allergy Vendor Cyber Rating & Cyber Score

hsallergy.com

Add Your Compliance Badge

In 1921, Guy Hollister, a chemist, and Dr. Robert Stier, a pathologist, developed a treatment to bring relief to the allergy suffering in their own families. From those beginnings a company dedicated to putting an end to allergy suffering was born, HollisterStier Allergy. Over the years that focus has not wavered, and our quest for better ways to do things continues. We take pride in the quality of our extracts, and our research and development group continually looks at ways to improve them. Our constant search for better ways to do things and an overwhelming need to help allergy sufferers get more out of life have led us to some unique products like our multiple skin test devices, and our phenol free antigens. And we are working on all

HollisterStier Allergy A.I CyberSecurity Scoring

Scoring History

HollisterStier Allergy

HollisterStier Allergy CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

HollisterStier Allergy Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for HollisterStier Allergy

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for HollisterStier Allergy in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for HollisterStier Allergy in 2026.

Incident Types HollisterStier Allergy vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for HollisterStier Allergy in 2026.

Incident History - HollisterStier Allergy (X = Date, Y = Severity)

Loading…

SUBSIDIARY

HollisterStier Allergy Subsidiaries

HollisterStier Allergy

Pharmaceutical Manufacturing

Website: http://www.hsallergy.com

Company Size: 126

Jubilant Pharmova LimitedPharmaceutical Manufacturing

Jubilant Biosys LimitedResearch

Jubilant Chemsys -> Jubilant Biosys LimitedPharmaceutical Manufacturing

Jubilant RadiopharmaPharmaceutical Manufacturing

Jubilant Pharma LimitedPharmaceutical Manufacturing

Jubilant Therapeutics IncBiotechnology

Jubilant Generics LimitedPharmaceutical Manufacturing

Jubilant Life Sciences Alumni NetworkPharmaceutical Manufacturing

Jubilant HollisterStier CMOPharmaceutical Manufacturing

Sterile Ophthalmics & OticsPackaging & Containers

Non-Sterile Topicals and LiquidsPharmaceutical Manufacturing

High Speed Ampoule FillingPharmaceutical Manufacturing

Jubilant Cadista PharmaceuticalsPharmaceutical Manufacturing

Loading…

HollisterStier Allergy Similar Companies

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Loading…

NEWS

HollisterStier Allergy CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-48777

SUMMARY

FileBrowser Quantum is a free, self-hosted, web-based file manager. Versions prior to 1.3.2-stable, 1.4.0-beta and 1.4.1-beta are vulnerable to Path Traversal through the publicPatchHandler in backend/http/public.go which joins user-controlled fromPath and toPath body fields with the trusted d.share.Path BEFORE the downstream sanitizer runs. Because filepath.Join collapses .. segments during the join, the sanitizer in resourcePatchHandler never sees the traversal and the move/copy/rename operates on a path outside the shared directory. The same root-cause pattern was patched for the bulk DELETE endpoint as CVE-2026-44542 (GHSA-fwj3-42wh-8673), but the PATCH handler with the identical pattern was not updated. A public share link with AllowModify=true is sufficient to exploit this. Anyone holding such a link can move, copy, or rename arbitrary files within the share owner's source root. This issue has been fixed in versions 1.3.3-stable and 1.4.2-beta.

Published

Date2026-06-16

Updated

Date2026-06-16

RISK INFORMATION (Score: )

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-47750

SUMMARY

stable-diffusion.cpp is a pure C/C++ library for running diffusion model (Stable Diffusion, Flux, Wan, Qwen Image, Z-Image, and more) inference. In versions prior to master-584-0a7ae07, the pickle .ckpt parser in src/model.cpp contained a heap buffer overflow vulnerability in the GLOBAL opcode handler. The issue was caused by missing validation when searching for newline-delimited fields. A crafted .ckpt file without the expected newline could cause the parser to use -1 as a copy length, resulting in immediate heap corruption. The attack requires the victim or application to load a .ckpt file from an untrusted source, such as a downloaded model from a model sharing site. The issue has been resolved in version master-584-0a7ae07. If developers are unable to immediately update their applications they can work around this issue by following these instructions: do not load .ckpt checkpoint files from untrusted sources, and prefer trusted model sources and safer formats such as .safetensors where possible.

Published

Date2026-06-16

Updated

Date2026-06-16

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-47747

SUMMARY

stable-diffusion.cpp is a pure C/C++ library for running diffusion model (Stable Diffusion, Flux, Wan, Qwen Image, Z-Image, and more) inference. In versions prior to master-584-0a7ae07, the pickle .ckpt parser in src/model.cpp contained a heap buffer overflow vulnerability in the BINUNICODE opcode handler. The issue was caused by sign confusion on the opcode length field. A crafted .ckpt file could trigger memcpy with a very large length derived from a negative signed value, causing immediate heap corruption. The issue has been resolved in version master-584-0a7ae07. If developers are unable to immediately update their applications they can work around this issue by only loading .ckpt checkpoint files from trusted sources and preferring trusted model sources and safer formats such as .safetensors where possible.

Published

Date2026-06-16

Updated

Date2026-06-16

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-46448

SUMMARY

In OpenStack Nova before 33.0.2, the server create API does not strip certain hint data. The resulting instance has no Placement allocation.

Published

Date2026-06-16

Updated

Date2026-06-16

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:L

Impact Score

2.5

Exploitability

2.8

REFERENCES

CVE-2026-22313

SUMMARY

The device has a webserver that exposes a REST API authenticated with a token on the management network. By exploiting an OS command injection vulnerability an authenticated attacker can send arbitrary commands to the device that are executed with administrative permissions by the underlying operating system.

Published

Date2026-06-16

Updated

Date2026-06-16

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:H/A:H

Impact Score

Exploitability

2.3

REFERENCES

https://www.cvcn.gov.it/cvcn/cve/CVE-2026-22313

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…